

DAFTAR PUSTAKA

1. Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. *European Respiratory Journal*. 2020;55(4):9–11.
2. Wu YC, Chen CS, Chan YJ. The outbreak of COVID-19: An overview. *Journal of the Chinese Medical Association*. Wolters Kluwer Health; 2020;83(3):217–20.
3. Beltrán-garcía J, Osca-verdegal R, Pallardó F V, Ferreres J, Rodríguez M, Mulet S, et al. Sepsis and Coronavirus Disease 2019 : Common Features and Anti-Inflammatory Therapeutic Approaches. *Social of Critical Care Medicine Wolters Kluwer Health*. 2020;(19):1–4.
4. Brandtner A, Tymoszek P, Nairz M, Lehner GF, Fritsche G, Vales A, et al. Linkage of alterations in systemic iron homeostasis to patients' outcome in sepsis: A prospective study. *Journal of Intensive Care*. 2020;8(1):1–13.
5. Ramos FJ da S, Freitas FGR de, Machado FR. Sepsis in patients hospitalized with coronavirus disease 2019 : how often and how severe ? *Wolters Kluwer Heal*. 2021;27(5):474–9.
6. Global Sepsis Alliance. COVID-19/CORONA VIRUS/SARS-COV-2. *Global Sepsis Alliance*. 2020: 1–14.
7. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet (London, England)*. 2020;395(10229):1054–62.
8. Garcia PCR, Longhi F, Branco RG, Piva JP, Lacks D, Tasker RC. Ferritin levels in children with severe sepsis and septic shock. *Acta Paediatrca*. 2007;96(12):1829–31.
9. Bennett TD, Hayward KN, Farris RWD, Ringold S, Wallace CA, Brogan T V. Very high serum ferritin levels are associated with increased mortality and critical care in pediatric patients. *Pediatric Critical Care Medicine*. 2011;12(6):233-6.
10. Carcillo JA, Kernan KK, Horvat CM. Why and How Is Hyperferritinemia Sepsis Different From Sepsis Without Hyperferritinemia? *Pediatr Crit Care*

Med. 2020;21(5):509–12.

11. Banchini F, Cattaneo GM, Capelli P. Serum ferritin levels in inflammation : a retrospective comparative analysis between COVID-19 and emergency surgical non-COVID-19 patients. *World Journal Emergency Surgery.* 2021;16 (1):1–7.
12. Abumayyaleh MS., Nuñez-Gil IJ, El-Battrawy I, Estrada V, Becerra-Muñoz VM, Uribarri A, et al. Sepsis of patients infected by SARS-CoV-2: Real-World Experience From the International HOPE-COVID-19-Registry and Validation of HOPE Sepsis Score.*Frontiers in Medicine.*2021;8:1-10.
- 13.13.Samuel MS, Latha R, Kavitha K, Sivasubramanian V. A study on biomarkers of sepsis and potential role of procalcitonin and ferritin marker in diagnosis, prognosis and treatment. *Journal of Family Medicine and Primary Care,* 2022; 11(6): 2608-12.
- 14.14.Kell DB, Pretorius E. Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells. *Metallomics.* 2014;6(4):748–73.
- 15.15.Sari EP, Medison I, Russilawati. Association Between Ferritin Levels and Severity of COVID-19 in RSUP Dr. M. Djamil. *Jurnal Respirologi Indonesia.* 2022;42:237–43.
- 16.16.Qin L, Li X, Shi J, Yu M, Wang K, Tao Y, et al. Gendered effects on inflammation reaction and outcome of COVID-19 patients in Wuhan. *Journal of Medical Virology.* 2020 Nov;92(11):2684–92.
- 17.17.Sun L, Shen L, Fan J, Gu F, Hu M, An Y, et al. Clinical features of patients with coronavirus disease 2019 from a designated hospital in Beijing, China. *Journal of Medical Virology.* 2020;92(10):2055–66.
- 18.18.Hou H, Zhang B, Huang H, Luo Y, Wu S, Tang G, et al. Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19. *Clinical & Experimental Immunology.* 2020 Jul;201(1):76–84.
19. Ochoa NEL, Rodríguez G, Reyes ID, Rivas KMR, Ramírez C, Durón R M. Differences in inflammatory markers between coronavirus disease 2019 and sepsis in hospitalized patients. *Clinical Epidemiology and Global Health,* 2022;15:1-6.

20. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. *JAMA*. 2020;324(8):782–93.
21. Hopkins J. COVID-19 dashboard by the center for science and engineering at Johns Hopkins University. 2020.
22. Stokes EK, LD Z, KN A. Coronavirus disease 2019 case surveillance - United States, January 22-May 30, 2020. *Morbidity and Mortality Weekly Report*. 2020;69(24):759–65.
23. National Institutes of Health. Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. 2021;1–243.
24. Sharma A, Farouk IA, Lal SK. COVID-19: A Review on the Novel Coronavirus Disease Evolution, Transmission, Detection, Control and Prevention. *MDPI*. 2021;13:1–25.
25. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *New England Journal of Medicine*. 2020;382(8):727–33.
26. Susilo A, Rumende CM, Pitoyo CW, Santoso WD, Yulianti M, Sinto R, et al. Coronavirus Disease 2019 : Review of Current Literatures. *Jurnal Penyakit Dalam Indonesia*. 2020;7(1):45–67.
27. Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. *Nature Microbiology*. 2020;5(4):536–44.
28. Kim D, Quinn J, Pinsky B, Shah NH BI. Rates of co-infection between SARS-CoV-2 and other respiratory pathogens. *JAMA*. 2020;20(323):2085–6.
29. Jawetz MS. Jawetz, Melnick, & Adelberg's Medical Microbiology. 28th ed. New York: McGraw-Hill Education/Medical; 2019. 617–22.
30. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. *Journal of Virology*. 2020;94(7):127-30.

31. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*. 2020;181(2):271-80.
32. Hancock AS, Stairiker CJ, Boesteanu AC, Monzón-Casanova E, Lukasiak S, Mueller YM, et al. Transcriptome Analysis of Infected and Bystander Type 2 Alveolar Epithelial Cells during Influenza A Virus Infection Reveals In Vivo Wnt Pathway Downregulation. *Journal of Virology*. 2018 ;92(21):1325-18.
33. Wu J, Wu X, Zeng W, Guo D, Fang Z, Chen L, et al. Chest CT Findings in Patients With Coronavirus Disease 2019 and Its Relationship With Clinical Features. *Investigative Radiology*. 2020;55(5):257–61.
34. Zhang S, Li H, Huang S, You W, Sun H. Early View High-resolution CT features of 17 cases of Corona. *European Respiratory Journal*. 2020;55 (4).
35. Yee M, Domm W, Gelein R, Bentley KL de M, Kottmann RM, Sime PJ, et al. Alternative Progenitor Lineages Regenerate the Adult Lung Depleted of Alveolar Epithelial Type 2 Cells. *American Journal of Respiratory Cell and Molecular Biology*. 2017;56(4):453–64.
36. Sugihantono A, Burhan E, Susanto AD. Pedoman Pencegahan dan Pengendalian Coronavirus Disease (COVID-19). Jakarta: Kementerian kesehatan RI; 2020. 19–132.
37. Aldhaleei WA, Alnuaimi A BA. COVID-19 induced hepatitis B virus reactivation: a novel case from the United Arab Emirates. *Cureus*. 2020;12(6):8645-8.
38. Xu R, Zhou Y CL. Co-reactivation of the human herpesvirus alpha subfamily (herpes simplex virus-1 and varicella zoster virus) in a critically ill patient with COVID-19. *British Journal Dermatology*.2020;183(6):1145-7
39. Marchese V, Crosato V GM. Strongyloides infection manifested during immunosuppressive therapy for SARS-CoV-2 pneumonia. *Infection*. 2021;49(3):539–42.
40. Singh AK, Singh R, Joshi SR MA. Mucormycosis in COVID-19: a

systematic review of cases reported worldwide and in India. *Diabetes Metabolism Syndrome*. 2021;15(4). 102146-8

41. Singer M, Deutschman CS, Seymour C. The third international consensus definitions for sepsis and septic shock (sepsis-3). *JAMA*. 2016;315:801–10.
42. Tufan ZK, Kayaaslan B, Mer M. COVID-19 and Sepsis. *Turkish Journal of Medical Sciences*. 2021. 51(7): 3301-11.
43. Dugar S, Choudhary C, Duggal A. Sepsis and septic shock : Guideline-based management. *Cleve Clin J Med*. 2022;87(1):53–64.
44. Hussein AM, Taha ZB, Gailan A, Akram K, Qasim D, Jalal R, et al. D-Dimer and Serum Ferritin as an Independent Risk Factor for Severity in COVID-19 Patients. *Elsevier*. 2021:1–3.
45. NQF revises sepsis measure. *National Quality Forum (NQF)*. 2002.
46. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. *Intensive Care Medicine*. 1996;22:707–10.
47. Cullis JO, Fitzsimons EJ, Griffiths WJH, Tsochatzis E, Thomas DW. Investigation and management of a raised serum ferritin. *British Journal of Haematology*. 2018;181(3):331–40.
48. Sandnes M, Ulvik RJ, Vorland M, Reikvam H. Hyperferritinemia — A Clinical Overview. *Journal of Clinical Medicine*. 2021;10(9),1-25.
49. Ellervik C, Marott JL, Tybjærg-Hansen A, Schnohr P, Nordestgaard BG. Total and cause-specific mortality by moderately and markedly increased ferritin concentrations: general population study and metaanalysis. *Clinical Chemistry*. 2014;60(11):1419–28.
50. Weis S, Carlos AR, Moita MR, Singh S, Blankenhau B, Cardoso S, et al. Metabolic adaptation establishes disease tolerance to sepsis. *Cell*. 2017; 169(7):1263-75.
51. Kernan KF, Carcillo JA. Hyperferritinemia and inflammation. *International Immunology*. 2017;29(9):401-9.
52. Song CY, Xu J, He JQ, Lu YQ. Immune dysfunction following COVID-19,

especially in severe patients. *Scientific Reports* . 2020;10(1):1–11.

53. Irvan I, Febyan F, Suparto S. Sepsis dan Tata Laksana Berdasar Guideline Terbaru. *JAI (Jurnal Anestesiologi Indonesia)*. 2018;10(1):62
54. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. *new England Journal of Medicine*. 2001. 344(10): 699-709.
55. Retamozo S, Brito-zerón P, Sisó-almirall A. Haemophagocytic syndrome and COVID-19. *Clinical Rheumatology*. 2021;40(4):1233–44.
56. Setiadi W, Rozi IE, Safari D, Daningrat WOD, Johar E, Yohan B, et al. Prevalence and epidemiological characteristics of COVID-19 after one year of pandemic in Jakarta and neighbouring areas, Indonesia: A single center study. *PLoS One*. 2022;17(5) May):1–9.
57. McLaughlin K-M, Bechtel M, Bojkova D, Münch C, Ciesek S, Wass MN, et al. COVID-19-Related Coagulopathy-Is Transferrin a Missing Link? *Diagnostics (Basel, Switzerland)*. 2020 Jul;10(8).
58. Goldstein E, Lipsitch M, Cevik M. On the Effect of Age on the Transmission of SARS-CoV-2 in Households, Schools, and the Community. *Journal of infectious diseases*. 2021 Feb 1;223(3):362–9.
59. Indriyani N, Sabri YS, Afriani A. Association Between Comorbidities and Outcome of COVID-19 Patients at Dr. M. Djamil General Hospital Padang. *Respiratory Science*. 2022; 3(1): 38-50.
60. Chicamy YA, Safitri A, Nindrea RD. Serum Ferritin Levels for the Prediction of Mortality among COVID-19 Patients in an Indonesia' s National Referral Hospital. 2022;10:1056–61.
61. Liu T, Zhang J, Yang Y, Ma H, Li Z, Zhang J, et al. The role of interleukin- 6 in monitoring severe cases of coronavirus disease 2019. *EMBO Mol Med*. 2020;12(7):1–12.
62. Chen J, Jiang Q, Xia X, Liu K, Yu Z, Tao W, et al. Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation. *Aging Cell*. 2020;19(7):1–12.
63. Lino K, Macedo G, Guimarães C, Santos L, Caroline A, Faustino R, et al.

- Serum ferritin at admission in hospitalized COVID-19 patients as a predictor of mortality. *Soc Bras Infectol*. 2021;5(2):1–6.
64. Krishnan A, Hamilton JP, Alqahtani SA, Woreta TA. A narrative review of coronavirus disease 2019 (COVID-19): clinical, epidemiological characteristics, and systemic manifestations. *Internal Emergency Medicine*. 2021;16(4):815–30.
 65. Cheng L, Li H, Li L, Liu C, Yan S, Chen H, et al. Ferritin in the coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. *J Clin Lab Anal*. 2020 Oct;34(10):1-18.
 66. Hippchen T, Altamura S, Muckenthaler MU, Merle U. Hypoferremia is Associated With Increased Hospitalization and Oxygen Demand in COVID-19 Patients. *HemaSphere*. 2020;4(6):1-9.
 67. Sawadogo W, Tsegaye M, Gizaw A, Adera T. Overweight and obesity as risk factors for COVID-19-associated hospitalizations and death: systematic review and meta-analysis. *BMJ Nutr Prev Heal*. 2022;5(1):10–8
 68. Tojo K, Sugawara Y, Oi Y, Ogawa F, Higurashi T, Yoshimura Y, et al. The U-shaped association of serum iron level with disease severity in adult hospitalized patients with COVID-19. *Scientific Reports*. 2021;11(1):1-7.
 69. Sonnweber T, Boehm A, Sahanic S, Pizzini A, Aichner M, Sonnweber B, et al. Persisting alterations of iron homeostasis in COVID-19 are associated with non-resolving lung pathologies and poor patients' performance: a prospective observational cohort study. *Respir Res*. 2020 Oct;21(1):1-9.
 70. Gómez-Pastora J, Weigand M, Kim J, Wu X, Strayer J, Palmer AF, et al. Hyperferritinemia in critically ill COVID-19 patients – Is ferritin the product of inflammation or a pathogenic mediator? *Clinica Chimica Acta International Journal of Clinical Chemistry*. 2020;509:249–51.
 71. Rajanna AH, Krishnegowda R, Govindaiah RM. To Correlate Serum Ferritin Levels with Clinical Outcome in Covid-19 Patients. *Asian J Med Sci*. 2021;12(5):25–9.
 72. Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, et al. Structural basis of receptor recognition by SARS-CoV-2. *Nature* [Internet]. 2020;581(7807):1-18.

73. Wern NH, Tipih T, Makoah NA, Vermeulen JG, Goedhals D, Sempa JB, et al. Comorbidities in SARS-CoV-2 patients: A systematic review and meta-analysis. *MBio*. 2021;12(1):1–12.
74. Suriawinata E, Mehta KJ. Iron and iron-related proteins in COVID-19. *Clinical and Experimental Medicine*. 2022;1-23.
75. Chen HY, Tzeng IS, Tsai KW, Wu YK, Cheng CF, Lu KC, et al. Association between heme oxygenase one and sepsis development in patients with moderate-to-critical COVID-19: a single-center, retrospective observational study. *European Journal of Medical Research*. 2022; 27(1): 275: 1-11.
- 76.76.Shappell CN, Klompas M, Kanjilal S, Chan C, Rhee C. Prevalence, clinical characteristics and outcomes of sepsis caused by severe acute respiratory syndrome coronavirus 2 versus other pathogens in hospitalized patients with COVID-19. *Critical care explorations*. 2022; 4(5):1-8.
- 77.77.Zheng KI, Gao F, Wang X-B, Sun Q-F, Pan K-H, Wang T-Y, et al. Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. *Metabolisme-clinical and experimental. United States*. 2020;108.
- 78.78.Rinaldy. Hubungan Kadar Ferritin Dengan Derajat Keparahan Pasien Covid-19. Universitas Airlangga. 2020.
- 79.79.Fang YP, Zhang HJ, Guo Z, Ren CH, Zhang YF, Liu Q, et al. 2022. Effect of Serum Ferritin on the Prognosis of Patients with Sepsis: Data from the MIMIC-IV Database. *Emergency Medicine International*. 2022: 1-10.
- 80.80. Kaushal K, Kaur H, Sarma P, Bhattacharyya A, Sharma DJ, Prajapat M, et al. Serum ferritin as a predictive biomarker in COVID-19. A systematic review, meta-analysis and meta-regression analysis. *Journal of Critical Care*. 2022 Feb;67:172–81.
81. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. *J Allergy Clin Immunol*. 2020;146(1):110–8.
82. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-infection and secondary infection in patients with

COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect.2020;26(12):1622–9.

